Eli Lilly reported a strong Q1 2026 with revenue up 55.5% to $19.8 billion and earnings per share beating estimates. Its drug Mounjaro became the world's top-selling medication, driving optimism and a raised full-year revenue forecast of $82-$85 billion. Analysts set a 12-month price target of $1,085, implying 14.3% upside, citing growth in new drugs like Foundayo and retatrutide. Risks include pricing pressure and reliance on key drugs, but the outlook remains positive if new products gain traction and international sales grow.
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
About 30 million Americans use GLP-1 drugs, which chemically suppress appetite and reduce fast food demand by 27-30%. This structural shift benefits companies like Amazon, which is expanding its pharmacy and delivery services; Eli Lilly, leading with...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
The investor highlights NVIDIA's massive revenue growth and cash flow, boosted by AI demand and strong capital returns. Eli Lilly impresses with high revenue growth driven by key drugs like Mounjaro and Foundayo, despite pricing pressures. Johnson & ...
